EFFICACY AND SAFETY OF INCRETIN THERAPY IN TYPE 2 DIABETES MELLITUS : THE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v8i11.1400Keywords:
Diabetes Mellitus, HbA1c, Hyperglycemia, Incretin TherapyAbstract
Hyperglycemia is the key sign of type 2 diabetes, which is a metabolic disorder characterised by an inadequate production of insulin as well as resistance to the action of insulin. As longitudinal studies of type 2 diabetes continue to provide evidence linking improved glycemic control with a reduction in the rates of diabetes-associated complications, there is a considerable interest in the therapy of type 2 diabetes, with a focus on the development and use of new agents that exhibit improved efficacy and safety in comparison to currently available medicines. Clinical use of incretin-based medicines is growing steadily, and there are numerous additional products being developed at this time. The individual mechanisms by which dual agonism of both GLP-1 and GIP receptors may improve glycemic control require further investigation. We conducted post hoc exploratory analyses of biomarkers associated with pancreatic beta-cell function and insulin sensitivity in order to investigate the mechanisms by which tirzepatide led to greater reductions of hyperglycemia than a selective GLP-1 receptor agonist. According to the findings of this paper, a dose of 15 milligrams of tizepatide was superior in reducing HbA1c levels, despite the fact that it induced higher levels of gastrointestinal side effects.
References
International Diabetes Federation. Diabetes. Brussels: IDF; 2017.
Fauci AS, Jameson JL, Kasper D, et al. Harrison’s Principles of Internal Medicine 19th Edition. New York: McGraw-Hill Education; 2018.
Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. Februari 2010;33(2):428–33.
Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules. April 2020;25(8).
Neumiller JJ. Incretin-based therapies. Med Clin North Am. Januari 2015;99(1):107–29.
Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S. Incretins: their physiology and application in the treatment of diabetes mellitus. Diabetes Metab Res Rev. Juli 2014;30(5):354–71.
Robertson C. Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview. Diabetes Spectr [Internet]. 1 Februari 2011;24(1):26–35. Tersedia pada: https://doi.org/10.2337/diaspect.24.1.26
Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol (Lausanne). 2020;11:178.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. Agustus 2021;385(6):503–15.
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). Juli 2021;398(10295):143–55.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet (London, England). November 2021;398(10313):1811–24.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet (London, England). November 2018;392(10160):2180–93.
Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med. Juli 2017;23(7):804–14.
Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother. November 2020;131:110708.
Chellappan DK, Yap WS, Bt Ahmad Suhaimi NA, Gupta G, Dua K. Current therapies and targets for type 2 diabetes mellitus. Panminerva Med. September 2018;60(3):117–31.
Sun J, Cui J, He Q, Chen Z, Arvan P, Liu M. Proinsulin misfolding and endoplasmic reticulum stress during the development and progression of diabetes. Mol Aspects Med. April 2015;42:105–18.
Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. Januari 2021;106(2):388–96.
Perreault L, Skyler JS, Rosenstock J. Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nat Rev Endocrinol. Juni 2021;17(6):364–77.
Vangipurapu J, Stan?áková A, Kuulasmaa T, Kuusisto J, Laakso M. Both fasting and glucose-stimulated proinsulin levels predict hyperglycemia and incident type 2 diabetes: a population-based study of 9,396 Finnish men. PLoS One. 2015;10(4):e0124028.
Ahrén B. Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med. Mei 2005;5(3):275–86.
Patel K, Levesque K, Mark V, Pierini E, Rojas B, Ahlers M, et al. Proinsulin associates with poor ?-cell function, glucose-dependent insulinotropic peptide, and insulin resistance in persistent type 2 diabetes after Roux-en-Y gastric bypass in humans. J Diabetes. Januari 2020;12(1):77–86.
Smith SA, Porter LE, Biswas N, Freed MI. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. J Clin Endocrinol Metab. Desember 2004;89(12):6048–53.
Lebovitz HE. Incretin-based therapies: facing the realities of benefits versus side effects. Vol. 15, Diabetes technology & therapeutics. 2013. hal. 909–13.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Journal of Advance Research in Medical & Health Science
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
